Supplier : CEGEDIM

Solution : Crossway practice management software used by private practitioners and Maiia digital assistance for booking appointments and communication between caregivers. 50 volunteer self-employed doctors equipped with the Cegedim software suite (Crossway with PLCOm2012noRace + Maiia + THIN®) in Ile de France.

Need: The aim of the Cross-Prev study is to evaluate the automated identification in GP practices of people at increased risk of lung cancer, and their direct referral to a GUSTAVE ROUSSY screening and prevention program via the medical software developed by CEGEDIM.

Tiers-Lieu's contribution: carry out a feasibility study with a view to deploying digital solutions on a larger scale. Interception has developed eligibility criteria for identifying patients at high risk of lung cancer, and these patients referred by private practitioners benefit from a day of prevention and screening.

Interception's contribution: to carry out a feasibility study with a view to deploying the digital solutions on a wider scale.

• The first innovation lies in the integration of the validated lung cancer risk assessment score PLCOm2012noRace into the Crossway practice management software used by thousands of private practitioners.
• The second innovation lies in the direct and rapid referral to INTERCEPTION of patients who accept the treatment proposed by their doctor, through Maiia (digital assistance for booking appointments and communication between caregivers).
  

Supplier : Gustave Roussy

Solution : non-healthcare professionals can access a free self-administered online questionnaire to test whether they have a high risk of cancer and whether they are then eligible for specific care.

Need : The Scorisk4all study aims to evaluate the relevance of the ScoRisk-4-all questionnaire for cancer risk self-assessment by non-healthcare professionals.

Tiers Lieu's contribution: to carry out a study of the relevance and feasibility of self-identification of high-risk cancer situations using an online questionnaire combined with algorithms. Several cohorts of unaffected individuals will take part in this self-identification pilot study. Self-identification enables direct referral to an INTERCEPTION pathway.

Supplier : CEGEDIM, help with conception and design, deployment and testing: Tiers Lieu partners including user associations.

Solution : Free access to Maiia version 2.0 software for the duration of the study (2 years) for Interception patients and their attending physicians. Pilot Ile de France, then Rhône Alpes extension around the Léon Bérard center, then multicenter deployment.

Need: to evaluate the use of version 2 of Maiia's marketed digital assistance to meet the needs of personalized prevention plan follow-up after the Interception day.

Tiers Lieu contribution: offer coordinated city-hospital follow-up focused on the patient at high risk of cancer and included in a specific screening and prevention Interception pathway, including immediate care in the event of an abnormal examination or symptom.
The Mon Suivi INTERCEPTION pilot study aims to evaluate the use of version 2 of Maiia's marketed digital assistance to meet the needs of personalized prevention plan follow-up after the Interception day.

• The first innovation lies in direct communication with the patient and attending physician via the Interception platform. This enables automatic reminders, document exchanges and the dissemination of information on screening and prevention.
• The second innovation lies in the existence of a HOTLINE in the event of suspected cancer, enabling rapid referral to a diagnosis and management program.